Accendra Health Analyst Price Targets - Benzinga

Accendra Health Inc

ACHNYSE

Trade with Public

Trade with Public

$0.4792

0.02826.24%

마지막 업데이트: Oct 6, 1:13 PM

$0.4650

0.0143.1%

개요 뉴스 실적 전망목표가재무 심리 비교 옵션 주식 보고서

Accendra Health Analyst Price Targets - Benzinga

Accendra Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Accendra Health (ACH).

Price Target Range — 3 Quarters

Analyst Consensus — 4 Analysts

1Buy

3Hold

Consensus RatingNeutral# Analysts4Avg. Consensus PT$3Upside to Avg. PT+513.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	UBS	Kevin Caliendo	PT Cut	Neutral	$5→$2
Aug 11, 2026	Citigroup	Daniel Grosslight	Downgrade	Buy→Neutral	$5→$2
Jul 24, 2026	Citigroup	Daniel Grosslight	PT Cut	Buy	$5→$5
May 12, 2026	UBS	Kevin Caliendo	PT Raise	Neutral	$3→$5
May 12, 2026	Citigroup	Daniel Grosslight	PT Raise	Buy	$3→$5
May 12, 2026	Baird	Eric Coldwell	PT Raise	Outperform	$5→$6
Feb 20, 2026	Leerink Partners	Michael Cherny	PT Cut	Market Perform	$3→$3
Jan 9, 2026	Citigroup	Daniel Grosslight	PT Cut	Buy	$7→$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Neutral on Accendra Health, Lowers Price Target to $1.5

UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and lowers the price target from $4.5 to $1.5.

Benzinga Newsdesk

PRO
Citigroup Downgrades Accendra Health to Neutral, Lowers Price Target to $1.5

Citigroup analyst Daniel Grosslight downgrades Accendra Health (NYSE:ACH) from Buy to Neutral and lowers the price target from $4.5 to $1.5.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Accendra Health, Lowers Price Target to $4.5

Citigroup analyst Daniel Grosslight maintains Accendra Health (NYSE:ACH) with a Buy and lowers the price target from $5 to $4.5.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on Accendra Health, Raises Price Target to $4.5

UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and raises the price target from $3 to $4.5.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Accendra Health, Raises Price Target to $5

Citigroup analyst Daniel Grosslight maintains Accendra Health (NYSE:ACH) with a Buy and raises the price target from $3.25 to $5.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Accendra Health, Raises Price Target to $6

Baird analyst Eric Coldwell maintains Accendra Health (NYSE:ACH) with a Outperform and raises the price target from $5 to $6.

Benzinga Newsdesk